Nurix Therapeutics (NASDAQ:NRIX) Issues Earnings Results

Nurix Therapeutics (NASDAQ:NRIX) announced its quarterly earnings data on Tuesday. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08), Zacks reports. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%.

Nurix Therapeutics Trading Up 0.5 %

NRIX stock opened at $19.74 on Thursday. The business’s 50 day moving average is $20.14 and its 200-day moving average is $22.40. The firm has a market cap of $1.40 billion, a P/E ratio of -6.79 and a beta of 2.14. Nurix Therapeutics has a 1-year low of $7.79 and a 1-year high of $29.56.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on NRIX shares. UBS Group began coverage on Nurix Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $35.00 price target for the company. Needham & Company LLC lowered their price target on shares of Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday. Stephens reiterated an “overweight” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. HC Wainwright upped their target price on shares of Nurix Therapeutics from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, BMO Capital Markets initiated coverage on shares of Nurix Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $35.00 price target on the stock. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.71.

Insiders Place Their Bets

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,546 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $24.28, for a total value of $86,096.88. Following the transaction, the chief financial officer now owns 33,724 shares of the company’s stock, valued at approximately $818,818.72. The trade was a 9.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.20% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.